Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Likely To Lose Cost-Watchdog Status By 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

A new value-based pricing system will make NICE's cost-assessment role redundant, say U.K. ministers.

You may also be interested in...



NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms

NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.

NICE Will Have Key Role in Value-Based Pricing Under U.K. Health Care Reforms

NICE to be placed on a firmer statutory footing and given a new name, as well as a role in determining the value of medicines.

Avastin's Stumble Again At NICE Underscores Importance Of Overall Survival Data

NICE rejection of Roche's Avastin comes a week ahead of target dates for U.S. and EU decisions on possibly withdrawing the indication, but still offers instructive lessons for working with technology assessment groups.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel